Mr. Centanni has over 25 years of regulatory and product development experience, with a focus on biologic products. Prior to Joining Coya, he headed the Advanced Therapy Product Development team at Cardinal Health Regulatory Sciences. In this role, he served as the lead regulatory consultant for several biotech companies developing a wide range of Advance Therapy Products (autologous & allogeneic therapies, regenerative medicine products, and other immunomodulatory biologics). Mr. Centanni also served as the Vice President of Regulatory Affairs at Neurona Therapeutics, where he led the regulatory efforts in the development of stem cell therapy products for neurologic disorders. Prior to joining Neurona, he headed the regulatory program for biologics in support of AxoGen’s peripheral nerve tissue regeneration platform.
Mr. Centanni served as a Faculty Associate and Director of the IND/IDE Consultation Team at the University of Wisconsin-Madison where he provided FDA regulatory affairs support across campus to facilitate the success of numerous investigational new drug (IND) applications and associated IND-enabling studies leading to active early phase clinical trials for new therapies. Key areas of activities include providing regulatory affairs support for the Waisman Biomanufacturing Facility and serving as a faculty member of the University of Wisconsin-Madison, Master’s in Biotechnology Program.
Additionally, Mr. Centanni is an accomplished molecular and cellular biologist having led multi-million dollar federally funded clinical and translational research projects at the capacity of Principal Investigator. He has an established track record as it relates to scientific publications and generation of intellectual property as an inventor with an extensive patent portfolio.
Mr. Centanni received his M.S. in Biomedical Science from Hood College, Fredrick, Maryland and his B.S. in Biology from University of Wisconsin-Oshkosh.